A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
To learn if rivoceranib can help to control olfactory neuroblastoma. The safety of this drug in participants with olfactory neuroblastoma will also be studied.
Metastatic Olfactory Neuroblastoma|Recurrent Olfactory Neuroblastoma
DRUG: Rivoceranib
Safety and Adverse Events (AEs), Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0, Through study completion; an average of 1 year.
Primary Objective:

- To assess the efficacy of rivoceranib in patients with R/M ONB

Secondary Objective:

* To estimate the median duration of response (DOR)
* Time to response
* To estimate the median progression-free survival (PFS)
* To estimate the median overall survival (OS)
* To assess safety of rivoceranib

Tertiary Objective:

- To explore biomarkers that may predict response to therapy